COMPANY PROFILE

Telormedix

Explore full profile

Focused on targeted immunity - Telormedix

Bioggio, SwitzerlandFounded 2007Biotech & Life Sciences

Valuation $25–50M Last recorded · 2013

Revenue $1–10M Latest reported FY

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Telormedix

Telormedix operates in the biopharmaceutical sector, specializing in treatments for chronic and acute pain, particularly related to sports injuries. The company serves patients suffering from hip pain and other sports-related injuries, offering both immediate pain relief and long-term cell regeneration therapies. Telormedix integrates its services within sports medicine centers and departments of physical and occupational therapy, ensuring a comprehensive approach to patient care. The business model revolves around providing specialized biopharmaceutical treatments and ongoing maintenance therapies, generating revenue through patient treatments and possibly through partnerships with healthcare providers. The company aims to improve patient outcomes through innovative research and precision medicine.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2007
Headquarters: Bioggio, Switzerland
Open positions: None listed
Dealroom signal: 23.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Immune System, Hard Tech, Longevity, Horizon Europe, DT and LS, science-based, Swiss DT Biotech
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Jan 2015	$0	—	Undisclosed	—
SERIES BEquity / VC	Dec 2013	$6.8M	$27M	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Telormedix website traffic

Latest recorded traffic for Telormedix is 160 monthly website visits.

Latest monthly visits160

Monthly website visitsDec 2016–Apr 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBioticaFast microbial detection techniques combining immunomagnetic capture and enzyme immunoassay (C.E.I.A.)	Spain	Closed	6	$2M	$3.1M
ATAffimed TherapeuticsNASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies	Heidelberg, Germany	Operational
SBSphere BioEnabling rapid screening and characterisation of single cells	Cambridge, United Kingdom	Operational
SPSpacePharmaUnique powerhouse offering an affordable and accessible microgravity, together with true innovation to R&D pipelines	Courgenay, Switzerland	Operational
MTMemo TherapeuticsAn innovator in the field of antibody discovery and immune repertoire analysis	Schlieren, Switzerland	Acquired
TTTargImmune TherapeuticsDeveloping novel targeted immuno-oncology drugs	Basel, Switzerland	Acquired
CYCytosDeveloping novel biologic immunotherapies for chronic diseases	Schlieren, Switzerland	Acquired
MPMetys PharmaceuticalsDeveloping dimiracetam for the prevention of chemotherapy-induced painful peripheral neuropathy	Basel, Switzerland	Acquired